Nivo-lution in mesothelioma Editorial
| Authors: | Mansfield, A. S.; Zauderer, M. G. |
| Title: | Nivo-lution in mesothelioma |
| Abstract: | The MERIT study was a single-arm, phase II clinical trial of nivolumab for the second- or third-line treatment of patients with malignant pleural mesothelioma in Japan. MERIT confirmed that PD-1 inhibition has activity in mesothelioma and led to the regulatory approval of nivolumab for the treatment of mesothelioma in Japan. © 2019 American Association for Cancer Research. |
| Journal Title: | Clinical Cancer Research |
| Volume: | 25 |
| Issue: | 18 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2019-09-15 |
| Start Page: | 5438 |
| End Page: | 5440 |
| Language: | English |
| DOI: | 10.1158/1078-0432.Ccr-19-1836 |
| PUBMED: | 31315884 |
| PROVIDER: | scopus |
| PMCID: | PMC6744981 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 October 2019 -- Source: Scopus |
